Evidence map›Paper›PMID 38463395›Full record

ArticleMedComm2024

Current clinical findings of acute neurological syndromes after SARS-CoV-2 infection.

Minjin Wang, Jierui Wang, Yan Ren, Lu Lu, Weixi Xiong, Lifeng Li, Songtao Xu, Meng Tang, Yushang Yuan, Yi Xie and 5 more

Abstract read
In one paragraph

Article in MedComm, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Minjin WangDepartment of Neurology West China Hospital of Sichuan University Chengdu Sichuan China.
Jierui WangDepartment of Neurology West China Hospital of Sichuan University Chengdu Sichuan China.
Yan RenDepartment of Laboratory Medicine West China Hospital of Sichuan University Chengdu Sichuan China.
Lu LuDepartment of Neurology West China Hospital of Sichuan University Chengdu Sichuan China.
Weixi XiongDepartment of Neurology West China Hospital of Sichuan University Chengdu Sichuan China.
Lifeng LiGenskey Medical biotechnology Company Limited Beijing China.
Songtao XuNational Institute for Viral Disease Control and Prevention Chinese Center for Disease Control and Prevention Beijing China.
Meng TangDepartment of Laboratory Medicine West China Hospital of Sichuan University Chengdu Sichuan China.
Yushang YuanDepartment of Laboratory Medicine West China Hospital of Sichuan University Chengdu Sichuan China.
Yi XieDepartment of Laboratory Medicine West China Hospital of Sichuan University Chengdu Sichuan China.
Weimin LiDepartment of Respiratory and Critical Care Medicine West China Hospital Sichuan University Chengdu Sichuan China.
Lei ChenDepartment of Neurology West China Hospital of Sichuan University Chengdu Sichuan China.ORCID https://orcid.org/0000-0001-5263-5540
Dong ZhouDepartment of Neurology West China Hospital of Sichuan University Chengdu Sichuan China.
Binwu YingDepartment of Laboratory Medicine West China Hospital of Sichuan University Chengdu Sichuan China.
Jinmei LiDepartment of Neurology West China Hospital of Sichuan University Chengdu Sichuan China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuro-COVID, a condition marked by persistent symptoms post-COVID-19 infection, notably affects various organs, with a particular focus on the central nervous system (CNS). Despite scant evidence of SARS-CoV-2 invasion in the CNS, the increasing incidence of Neuro-COVID cases indicates the onset of acute neurological symptoms early in infection. The Omicron variant, distinguished by heightened neurotropism, penetrates the CNS via the olfactory bulb. This direct invasion induces inflammation and neuronal damage, emphasizing the need for vigilance regarding potential neurological complications. Our multicenter study represents a groundbreaking revelation, documenting the definite presence of SARS-CoV-2 in the cerebrospinal fluid (CSF) of a significant proportion of Neuro-COVID patients. Furthermore, notable differences emerged between RNA-CSF-positive and negative patients, encompassing aspects such as blood-brain barrier integrity, extent of neuronal damage, and the activation status of inflammation. Despite inherent limitations, this research provides pivotal insights into the intricate interplay between SARS-CoV-2 and the CNS, underscoring the necessity for ongoing research to fully comprehend the virus's enduring effects on the CNS. The findings underscore the urgency of continuous investigation Neuro-COVID to unravel the complexities of this relationship, and pivotal in addressing the long-term consequences of COVID-19 on neurological health.

Indexed as

central nerve injuryNeuro‐COVIDneurological syndromesneurotropic invasionSARS‐CoV‐2

Identifiers

PMID38463395
PMCPMC10924641

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.